<DOC>
	<DOC>NCT00502463</DOC>
	<brief_summary>The purpose of the trial is to determine the feasibility of an induction chemotherapy with radio-immunotherapy in patients with head and neck cancer stage III/IV</brief_summary>
	<brief_title>Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial</brief_title>
	<detailed_description>3 Cycles of: Docetaxel 75 mg/m2 on d1, Cisplatin 75 mg/m2 on d1, 5-FU 750 mg/m2 on days 1-5 as continuous i.v. infusion, Duration of 1 cycle: 21 days; Followed by Cetuximab 400 mg/m2, Start of radiotherapy: 1 week after the first application of Cetuximab, During radiotherapy (35 x 2 Gy): Cetuximab 250 mg/m2 weekly, Up to 8 applications of Cetuximab.</detailed_description>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>histologically confirmed, locally advanced head and neck cancer stage III/IV performance status: ECOG 01 distant metastases prior radiotherapy of the head and neck region myocardial infarct in the last six months florid peptic ulcer neuropathy grade III/IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>head and neck cancer, stage III/IV</keyword>
	<keyword>no prior radiotherapy of head and neck region</keyword>
</DOC>